Home

Analítico Artefacto Motel teva laquinimod 2017 Goteo Bolsa Eh

Is Teva late reporting EU clinical trials?
Is Teva late reporting EU clinical trials?

Teva returns laquinimod global rights to Active Biotech
Teva returns laquinimod global rights to Active Biotech

PDF) Effect of laquinimod on gray matter and white matter atrophy in relapsing-remitting multiple sclerosis: analysis of the BRAVO phase III trial
PDF) Effect of laquinimod on gray matter and white matter atrophy in relapsing-remitting multiple sclerosis: analysis of the BRAVO phase III trial

MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease

Earnings Preview: What To Expect From Teva Pharmaceutical On Monday
Earnings Preview: What To Expect From Teva Pharmaceutical On Monday

Teva May Have to Make Difficult Capital Allocation Decisions Under Pressure From Potential Generic Competition, Deleveraging Goals - Reorg
Teva May Have to Make Difficult Capital Allocation Decisions Under Pressure From Potential Generic Competition, Deleveraging Goals - Reorg

Laquinimod (Nerventra, ABR-215062) - Multiple Sclerosis News Today
Laquinimod (Nerventra, ABR-215062) - Multiple Sclerosis News Today

Multiple Sclerosis: KOL Insight [2017]
Multiple Sclerosis: KOL Insight [2017]

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire

Teva Pharmaceuticals - Wikipedia
Teva Pharmaceuticals - Wikipedia

Teva Terminates TV-45070 Development Agreement with Xenon
Teva Terminates TV-45070 Development Agreement with Xenon

Patient enrollment in Phase III trial of laquinimod completed
Patient enrollment in Phase III trial of laquinimod completed

A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis | Neurology
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis | Neurology

Frontiers | Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea | Medicine
Frontiers | Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea | Medicine

MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS | Journal of Neuroinflammation | Full Text
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS | Journal of Neuroinflammation | Full Text

PDF) Laquinimod safety profile: Pooled analyses from the ALLEGRO and BRAVO trials
PDF) Laquinimod safety profile: Pooled analyses from the ALLEGRO and BRAVO trials

Multiple Sclerosis Clinical Trial Update: Laquinimod
Multiple Sclerosis Clinical Trial Update: Laquinimod

The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women | Request PDF
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women | Request PDF

Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis

PPMS Experimental Therapy Laquinimod Fails to Slow Brain Atrophy, Disease Progression
PPMS Experimental Therapy Laquinimod Fails to Slow Brain Atrophy, Disease Progression

Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint - Chemdiv
Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint - Chemdiv

Teva Archives - Pharmaceutical Technology
Teva Archives - Pharmaceutical Technology

PDF) Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis for the ALLEGRO Study Group
PDF) Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis for the ALLEGRO Study Group